-The Hindu Medicines remain overpriced and unaffordable in India. In a country mired in poverty, medical debt remains the second biggest factor for keeping millions in poverty. The international pharmaceutical industry has found its cash cow in India’s beleaguered consumers. With a minimum wage of Rs.250/day for a government worker, a basic wage worker afflicted with a chronic disease like multi-drug-resistant tuberculosis faces penury. His treatment, with drug combinations, which works out...

-The Times of India NEW DELHI: The government is set to expand the coverage of its Jan Aushadhi scheme. It will offer 439 life-saving medicines, including cancer and cardiovascular drugs, as well as 250 medical devices like stents and implants at 40-50% discounted prices. The department of pharmaceuticals plans to open 300 Jan Aushadhi stores across the country by March and another 3,000 by 2017. Presently, only 45 medicines are available in...

-The Hindu With the U.S. showing a preference for plurilateral agreements over WTO multilateralism, developing nations must defend the global trading system against transnational corporations The 10th Ministerial Conference of the World Trade Organisation (WTO), which also marked the completion of two decades of functioning of the most recent of the multilateral institutions, ended with an agreement among trade ministers of the member countries that may have pushed the organisation to the...

-The Times of India NEW DELHI: New medicines for treatment of diabetes, hypertension and pneumonia are set to be cheaper from Diwali. Drug price regulator National Pharmaceutical Pricing Authority (NPPA) has capped prices of as many as 18 new brands of essential medicines, most of which are expected to be launched in the market within a fortnight. The regulator has brought these medicines under price regulation using paragraph 5 of the Drugs...

-The Times of India MUMBAI: Certain medicines are being aggressively marketed in India despite inadequate evidence of safety and efficacy, putting patients at risk, said reputed medical journal Lancet. Highlighting weak regulation and monitoring of the domestic drug industry, three recently-introduced medicines are being prescribed and sold though there is a lack of rigorous trials on crucial safety and efficacy parameters. The pharmaceutical industry in India should face the same stringent regulations...